Anaptysbio (ANAB) Receivables (2016 - 2026)

Anaptysbio has reported Receivables for 10 years, with the latest figure at $25.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 43.97% year-over-year to $25.7 million; the trailing twelve-month figure through Mar 2026 stood at $25.7 million (up 43.97% YoY), and the FY2025 full-year result was $33.8 million, down 16.96% from the prior year.
• Receivables for Q1 2026 stood at $25.7 million, down from $33.8 million in the prior quarter.
• The five-year high for Receivables was $75.7 million in Q3 2025, with the low at $921000.0 in Q1 2022.
• Historically, Receivables has averaged $15.5 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables dropped 26.14% — and 2025, when it jumped 520.62%.
• Anaptysbio's Receivables stood at $1.4 million in 2022, then soared by 382.8% to $6.9 million in 2023, then soared by 495.02% to $40.8 million in 2024, then fell by 16.96% to $33.8 million in 2025, then retreated by 23.94% to $25.7 million in 2026.
• The last three Receivables figures came in at $25.7 million (Q1 2026), $33.8 million (Q4 2025), and $75.7 million (Q3 2025), per Business Quant data.